Companies in the News


VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Gritstone Oncology, a leader in personalized cancer immunotherapies, today a...


-- Expands technology and global footprint with acquisition of Humabs BioMed SA

-- Accesses clinical and preclinical stage assets from Alnylam, Visterra

-- Total financing to date exceeds $500 million

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Al...


Study conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

SAN DIEGO, October 4, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has initiated dosing in a Phase 2 clinical study...

Please reload